Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Grothey

Showing results (221-230 of 304) with videos related to

Pageof 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741Howard L McLeod, Daniel J Sargent, Sharon Marsh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancerDaniel J Sargent, Claus Henning Köhne, Hanna Kelly Sanoff, et al.
Cancers|May 28, 2020
<i>WRN</i>-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic PhenotypeKai Zimmer, Alberto Puccini, Joanne Xiu, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|November 22, 2018
Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal CancersLara F Nhola, Sahar S Abdelmoneim, Hector R Villarraga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)Deirdre R Pachman, Rui Qin, Drew K Seisler, et al.
Retina (Philadelphia, Pa.)|July 14, 2012
A factor found in the IgG fraction of serum of patients with paraneoplastic bilateral diffuse uveal melanocytic proliferation causes proliferation of cultured human melanocytesSarah L Miles, Richard M Niles, Sean Pittock, et al.
Nature Communications|January 15, 2025
Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, et al.
Nature Communications|November 25, 2024
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, et al.
JCO Precision Oncology|March 23, 2022
Landscape of <i>KRAS</i><sup>G12C</sup>, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in <i>KRAS</i>-Mutated CancersMohamed E Salem, Sherif M El-Refai, Wei Sha, et al.
The Oncologist|January 18, 2007
The continuum of care: a paradigm for the management of metastatic colorectal cancerRichard M Goldberg, Mace L Rothenberg, Eric Van Cutsem, et al.
Pageof 31

Showing results (221-230 of 304) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741Howard L McLeod, Daniel J Sargent, Sharon Marsh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancerDaniel J Sargent, Claus Henning Köhne, Hanna Kelly Sanoff, et al.
Cancers|May 28, 2020
<i>WRN</i>-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic PhenotypeKai Zimmer, Alberto Puccini, Joanne Xiu, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|November 22, 2018
Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal CancersLara F Nhola, Sahar S Abdelmoneim, Hector R Villarraga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)Deirdre R Pachman, Rui Qin, Drew K Seisler, et al.
Retina (Philadelphia, Pa.)|July 14, 2012
A factor found in the IgG fraction of serum of patients with paraneoplastic bilateral diffuse uveal melanocytic proliferation causes proliferation of cultured human melanocytesSarah L Miles, Richard M Niles, Sean Pittock, et al.
Nature Communications|January 15, 2025
Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, et al.
Nature Communications|November 25, 2024
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, et al.
JCO Precision Oncology|March 23, 2022
Landscape of <i>KRAS</i><sup>G12C</sup>, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in <i>KRAS</i>-Mutated CancersMohamed E Salem, Sherif M El-Refai, Wei Sha, et al.
The Oncologist|January 18, 2007
The continuum of care: a paradigm for the management of metastatic colorectal cancerRichard M Goldberg, Mace L Rothenberg, Eric Van Cutsem, et al.
Pageof 31